| Document |
Document Title |
|
WO/2023/158178A1 |
Disclosed are a peptide having antibacterial, anti-inflammatory, or tissue regeneration ability and use thereof. The peptide comprises an amino acid sequence of SEQ ID NO: 1.
|
|
WO/2023/158708A1 |
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodru...
|
|
WO/2023/156652A1 |
The present invention relates to antisense oligonucleotides that reduce expression of A1CF, as well as conjugates, salts and pharmaceutical compositions thereof. The invention also relates to uses of such antisense oligonucleotides, conj...
|
|
WO/2023/158616A1 |
The present disclosure is directed to oral dosage forms of TRβ agonist VK2809 and methods of preparing the same. The disclosure provides oral dosage forms of VK2809 with improved stability and solubility properties that allow for storag...
|
|
WO/2023/158024A1 |
The present invention relates to a composition for the prevention, amelioration or treatment of inflammatory bowel disease, comprising an Isodon excisus (Max.) Kudo-derived compound as an active ingredient. A compound represented by chem...
|
|
WO/2023/157990A1 |
The present invention relates to an oral film and a stick jelly which contain glutathione and various active ingredients, and the present invention provides an orally dissolving film, an oral mucoadhesive film and a stick jelly comprisin...
|
|
WO/2023/155568A1 |
Provided are Lactobacillus paracasei L511 with an inhibitory effect on the growth of a liver cancer tumor and use thereof. The strain has been deposited in China General Microbiological Culture Collection Center on January 14, 2022, unde...
|
|
WO/2023/155756A1 |
Disclosed in the present invention is the use of a lipoic acid nanoparticle in the preparation of a drug for treating diseases related to oxidative stress, which belongs to the technical field of biomedicine. The drug for treating diseas...
|
|
WO/2023/157776A1 |
In the present invention, it was found that due to the interaction of E-Syt1 on ER with PKCδ in liver cancer cells, PKCδ is secreted from the liver cancer cells by pathways via vesicular transport, and that the secretion of PKCδ from ...
|
|
WO/2023/156508A1 |
The present invention relates to compositions and kits comprising hyaluronic acid or a pharmaceutically acceptable salt thereof, and one or more inorganic peroxide (CaO2 ZnO2 and/or MgO2) for use in the prevention or treatment of wounds,...
|
|
WO/2023/155905A1 |
The present application relates to a compound of formula (I) and use thereof, and also relates to a method for preparing the compound.
|
|
WO/2023/152199A1 |
An oral composition comprising a zinc salt for use in a method for the enhancement of lysine biosynthesis within the mouth.
|
|
WO/2023/152234A1 |
The present invention relates to methods of stabilising proteins and peptides in the lower gastrointestinal tract. Pharmaceutical compositions which comprise as active ingredient a protein or a peptide; 5-aminolevulinic acid (5-ALA) or a...
|
|
WO/2023/150887A1 |
Compositions comprising a pre-SrnA1 peptide, an SrnA1 peptide, a pre-SrnA2 peptide, an SrnA2 peptide, a pre-SrnA4 peptide, a SrnA4, and other peptides and post-translationally modified versions thereof are taught. Also taught are methods...
|
|
WO/2023/150874A1 |
Crystalline Forms of a compound of Formula I are provided: (I) Crystalline Form C is among the crystalline Forms identified. Form C has an X-ray powder diffraction (XRPD) pattern having characteristic peaks expressed in degrees 2Ɵ (±0....
|
|
WO/2023/154953A1 |
The present disclosure provides methods of treating and preventing autoimmune disorders (e.g., multiple sclerosis (MS)), said methods comprising administering to a subject (e.g., a human) in need thereof a therapeutically effective amoun...
|
|
WO/2023/154770A1 |
The present invention provides for compositions and methods for treating a condition characterized by Rho-associated coiled-coil kinase (ROCK) activity in a subject in need thereof via administration of an effective amount of larazotide ...
|
|
WO/2023/152637A1 |
Insults to vital organs have serious and even life-threatening consequences. Organ insults have different etiologies and typically include drugs, toxins and ischemic insults. Acyl-CoA binding protein (ACBP), also known as diazepam-bindin...
|
|
WO/2023/154466A1 |
Arylbenzoisoxazole compounds of Formula (II), where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcohol...
|
|
WO/2023/153861A1 |
The present invention relates to a pharmaceutical composition comprising curcumin and ginsenoside, and a formulation comprising same. Using curcumin and ginsenoids according to the present invention in combination with butyric acid and s...
|
|
WO/2023/153777A1 |
The present invention relates to a composition for hangover relief, the composition comprising a Cucumis melo L. extract as an active ingredient. Specifically, the Cucumis melo L. extract can mitigate an increase in blood ethanol concent...
|
|
WO/2023/151358A1 |
The present invention relates to the field of pharmaceutical synthesis. Disclosed is a long-lasting hepatitis virus entry inhibitor. The long-lasting hepatitis virus entry inhibitor of the present invention is used for preparing a pharma...
|
|
WO/2023/152674A1 |
The present disclosure provides fixed dose combinations of Drotaverine or a salt thereof and benzodiazepines, methods of preparing fixed dose combinations, and their use in treatment.
|
|
WO/2023/152698A1 |
The present invention relates to compounds of formula (I): as activators of glucagon-like peptide 1 (GLP1) receptor for the treatment of obesity, type 2 diabetes mellitus, insulin resistance, hyperinsulinemia, glucose intolerance, hyperg...
|
|
WO/2023/153483A1 |
This composition for preventing or improving hepatic dysfunction contains glutathione trisulfide or a pharmacologically acceptable salt thereof.
|
|
WO/2023/150832A1 |
The present invention relates to processes for preparing compositions comprising manufactured bromoform and a bromoform stabilising excipient suitable for reducing total gas production and/or methane production and/or improving growth pe...
|
|
WO/2023/153903A1 |
The present invention relates to a composition for preventing or treating fatty liver disease, comprising Enterococcus faecalis as an active ingredient. Particularly, it has been identified that dead cells of Enterococcus faecalis EF-200...
|
|
WO/2023/151624A1 |
The use of an ASGR1 inhibitor in treating non-alcoholic fatty liver disease (NAFLD), the use of an ASGR1 inhibitor in promoting cholesterol efflux, the use of the combination of an ASGR1 inhibitor and a second lipid-lowering drug in trea...
|
|
WO/2023/153846A1 |
Disclosed is a treatment composition for calf diarrhea capable of significantly reducing the mortality of calves infected with diarrhea. The treatment composition for diarrhea according to the present invention comprises myrrh, frankince...
|
|
WO/2023/152415A1 |
The present invention relates to a compound of formula I, wherein the groups R1 to R5 and Cy have the meaning described in the description, for use thereof in the treatment and/or prevention of an infection or disease caused by the infec...
|
|
WO/2023/153479A1 |
A cell population which contains 75% or more of CD11b positive, F4/80 positive, CD180 positive and CD9 positive macrophages derived from a tissue selected from the group consisting of placenta, umbilical cord and amnion, and which contai...
|
|
WO/2023/153945A1 |
This invention relates to a combination, such as a composition, and its therapeutic and prophylactic uses. In particular (although not exclusively) the invention relates to a new method to modulate or treat the microbiome of an animal th...
|
|
WO/2023/150886A1 |
A strain of Streptococcus salivarius, probiotic mixtures and compositions have improved antimicrobial activity against Streptococcus mutans. Also provided are methods of preventing caries caused by Streptococcus mutans, comprising admini...
|
|
WO/2023/150759A1 |
The present disclosure provides a method of reducing body weight, body fat mass, liver fat in a subject who has an abnormal HbA1c level, comprising administering to the subject a therapeutically effective amount of 5-[(2,4-initrophenoxy)...
|
|
WO/2023/148783A1 |
The invention provides a novel, economical and practical route for the synthesis of an ester from acid and alcoholic functionalities using Trihalotriazine as coupling agent. Specifically, the invention provides a novel, economical and pr...
|
|
WO/2023/150108A1 |
The present disclosure is directed to an extended release composition containing one or more Boswellia derived compounds in a lipid matrix, which releases the Boswellia derived compound over a period of time. In one embodiment, the compo...
|
|
WO/2023/149768A1 |
A deubiquitinase inhibitor of the present invention can inhibit the expression of the deubiquitination enzymes USP42 and TRABID to increase the degradation of endoplasmic reticulum stress proteins, thereby exhibiting effects of preventin...
|
|
WO/2023/149512A1 |
The purpose of the present invention is to provide a protein deamidase agent having improved thermal stability. A guanidinium compound and polyamine can improve the thermal stability of a protein deamidase.
|
|
WO/2023/148670A1 |
Compositions comprising a solid dispersion of quercetin are useful in the treatment and/or prevention of ocular affections.
|
|
WO/2023/150241A1 |
Disclosed herein are methods for the treatment or prevention of topical or oral microbiome dysfunction in a subject in need thereof. The methods comprise the step of administering to the subject a compound capable of signaling the reduct...
|
|
WO/2023/148600A1 |
A monophasic, hydroalcoholic gel for topical drug delivery, comprising diclofenac epolamine or diclofenac diethylammonium, in a concentration of about 0.5% to about 1.5% w/w, a C2-C4- monoalcohol, in a concentration of about 12% to about...
|
|
WO/2023/149422A1 |
Provided is an agent for improving intestinal bacteria, comprising a proteolytic enzyme-decomposed residue of a soybean protein material. The agent suppresses proliferation of opportunistic bacteria.
|
|
WO/2023/150197A1 |
The present invention relates to pharmaceutical compounds of Formula (I): as further described herein, and pharmaceutical compositions containing such compounds, as well as methods of using these compounds to modulate the activity of ary...
|
|
WO/2023/149554A1 |
The purpose of the present invention is to provide novel lactic acid bacterium-containing tablets. The present invention provides lactic acid bacterium-containing tablets that comprise (A) a lactic acid bacterium, (B) an excipient and (C...
|
|
WO/2023/150767A1 |
The present disclosure provides a method of preserving skeletal muscle mass during weight loss.
|
|
WO/2023/147665A1 |
The present disclosure relates to compositions for improving gut health and/or milk production in ruminants, comprising: at least one organic acid chosen from sorbic acid, fumaric acid, malic acid, lactic acid, citric acid, formic acid, ...
|
|
WO/2023/148894A1 |
Provided are: an antibody which specifically binds to and neutralizes USAG-1 or an antigen-binding fragment thereof; and a pharmaceutical composition containing the antibody or the antigen-binding fragment.
|
|
WO/2023/145959A1 |
A medicine for treating or preventing interstitial lung disease and the disease or symptoms associated with systemic scleroderma in a subject, said medicine containing, as an active ingredient, 1-\{2-[(3S,4R)-1-\{[(3R,4R)-1-cyclopentyl-3...
|
|
WO/2023/146512A1 |
Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating diseases. Specific diseases include those that are mediated by YAP/TAZ or those that are modulated by the interaction be...
|
|
WO/2023/143571A1 |
Provided in the present invention is a ligand containing N-acetylgalactosamine, wherein the ligand contains a conjugated group as represented by formula (X') and a nucleic acid molecule containing the targeting ligand.
|
